Status:
COMPLETED
Sildenafil Citrate and Intrapartum Fetal Distress
Lead Sponsor:
Assiut University
Conditions:
Fetal Distress
Eligibility:
FEMALE
Phase:
PHASE4
Brief Summary
Induction of labour (IOL) is done for 20% of pregnancies for various maternal and fetal indications and nearly 20% of labour inductions end up in caesarean section. The most common causes are failed i...
Eligibility Criteria
Inclusion
- Singleton pregnancy.
- Pregnant ≥ 37 weeks gestation.
- Fetus with longitudinal lie and vertex presentation.
- Healthy fetus with EFW\>2500 gm
Exclusion
- Patients with previous cesarean delivery or uterine surgery.
- Antepartum hemorrhage.
- Cephalopelvic disproportion.
- Category II or III non-stress test.
- Medical disease as hypertension, cardiac, renal and hepatic disorders
- Intrauterine fetal death.
- Fetal growth restriction.
- Fetuses with major congenital malformations.
- Women taking any anti-hypertensive medication, alpha-adrenergic blocking agents, calcium channel blockers (verapamil), nitrates, medications used to treat pulmonary arterial hypertension, and other phosphodiesterase type 5 inhibitors.
- Women with a contra-indication to sildenafil treatment such as hypersensitivity to sildenafil.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
410 Patients enrolled
Trial Details
Trial ID
NCT04325243
Start Date
September 1 2020
End Date
July 31 2022
Last Update
January 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmed Abbas
Assiut, Cairo Governorate, Egypt, 002